Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Celldex Therapeutics, Inc. (CLDX : NSDQ)
 
 • Company Description   
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.

Number of Employees: 148

 
 • Price / Volume Information   
Yesterday's Closing Price: $32.13 Daily Weekly Monthly
20 Day Moving Average: 369,020 shares
Shares Outstanding: 47.25 (millions)
Market Capitalization: $1,518.22 (millions)
Beta: 2.12
52 Week High: $48.40
52 Week Low: $19.85
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.03% -1.83%
12 Week -27.31% -32.52%
Year To Date -27.91% -34.43%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
53 FRONTAGE ROAD SUITE 220
-
HAMPTON,NJ 08827
USA
ph: 908-200-7500
fax: 908-454-1911
ir@celldex.com http://www.celldex.com
 
 • General Corporate Information   
Officers
Anthony S. Marucci - President; Chief Executive Officer and Director
Karen L. Shoos - Chairman and Director
Sam Martin - Senior Vice President;Chief Financial Officer and
Keith L. Brownlie - Director
Cheryl L. Cohen - Director

Peer Information
Celldex Therapeutics, Inc. (CORR.)
Celldex Therapeutics, Inc. (RSPI)
Celldex Therapeutics, Inc. (CGXP)
Celldex Therapeutics, Inc. (BGEN)
Celldex Therapeutics, Inc. (GTBP)
Celldex Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 15117B202
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/14/23
Share - Related Items
Shares Outstanding: 47.25
Most Recent Split Date: 2.00 (0.07:1)
Beta: 2.12
Market Capitalization: $1,518.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.64 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.64 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.01
Price/Cash Flow: -
Price / Sales: 481.97
EPS Growth
vs. Year Ago Period: -26.53%
vs. Previous Quarter: -10.71%
Sales Growth
vs. Year Ago Period: 455.75%
vs. Previous Quarter: -40.05%
ROE
03/31/23 - -32.84
12/31/22 - -28.90
09/30/22 - -25.47
ROA
03/31/23 - -30.35
12/31/22 - -26.77
09/30/22 - -23.72
Current Ratio
03/31/23 - 19.03
12/31/22 - 17.07
09/30/22 - 20.54
Quick Ratio
03/31/23 - 19.03
12/31/22 - 17.07
09/30/22 - 20.54
Operating Margin
03/31/23 - -3,490.86
12/31/22 - -4,397.58
09/30/22 - -9,035.47
Net Margin
03/31/23 - -3,766.22
12/31/22 - -4,765.59
09/30/22 - -9,840.85
Pre-Tax Margin
03/31/23 - -3,766.22
12/31/22 - -4,765.59
09/30/22 - -9,840.85
Book Value
03/31/23 - 6.41
12/31/22 - 6.93
09/30/22 - 7.39
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.00
12/31/22 - 0.01
09/30/22 - 0.00
Debt-to-Capital
03/31/23 - 0.00
12/31/22 - 0.79
09/30/22 - 0.00
 

Powered by Zacks Investment Research ©